Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Interpretation of PSMA-PET Among Urologists: A Prospective Multicentric Evaluation
0
Zitationen
22
Autoren
2025
Jahr
Abstract
BACKGROUND: Prostate-specific membrane antigen (PSMA)-PET imaging has significantly improved prostate cancer (PCa) staging, yet its interpretation remains challenging, even for experienced specialists. No prior study has assessed urologists' ability to interpret PSMA-PET. METHODS: We conducted a multicenter prospective study involving 63 urologists from eight Italian institutions. Participants evaluated 20 PSMA-PET scans of high-risk PCa cases, with no clinical information provided. Proficiency was defined as correctly identifying at least two of three staging components (T, N, M) in ≥75% of cases. Associations between performance and factors such as hierarchy (resident vs. consultant), institution type, surgical volume, and multidisciplinary team (MDT) presence were analyzed using univariable and multivariable logistic regression. RESULTS: Only one participant achieved full staging proficiency, while 44% reached the ≥75% threshold for partial (almost correct) staging. Urologists from centers with ≥300 PCa diagnoses per year demonstrated better T and M stage identification. Institutions with ≥150 robot-assisted radical prostatectomies (RARPs) per year and those with MDTs showed higher accuracy in M staging. No significant predictors of proficiency emerged in the multivariable analysis, although hierarchy and surgical volume approached significance for nodal metastasis detection. CONCLUSION: PSMA-PET interpretation is complex for urologists, with particular challenges in T and M staging. High institutional case volumes and MDT involvement may enhance interpretation skills. Structured training programs and increased exposure to multidisciplinary imaging discussions are essential to optimize urologists' diagnostic proficiency and ultimately improve patient care.
Ähnliche Arbeiten
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 · 5.710 Zit.
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 · 5.464 Zit.
Decision Curve Analysis: A Novel Method for Evaluating Prediction Models
2006 · 5.218 Zit.
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 · 4.552 Zit.
Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer
1998 · 4.499 Zit.
Autoren
- Guglielmo Mantica
- Francesco Chierigo
- Francesca Ambrosini
- Francesca D’Amico
- Greta Celesti
- Arianna Ferrari
- Fabrizio Gallo
- Maurizio Schenone
- Andrea Benelli
- Carlo Introini
- Rosario Leonardi
- Alessandro Calarco
- Francesco Esperto
- Andrea Pacchetti
- Rocco Papalia
- Giorgio Bozzini
- Armando Serao
- Valentina Pau
- Gianmario Sambuceti
- Carlo Terrone
- Giuseppe Fornarini
- Matteo Bauckneht
Institutionen
- Ospedale Policlinico San Martino(IT)
- University of Genoa(IT)
- University of Messina(IT)
- Ente Ospedaliero Ospedali Galliera(IT)
- Ospedale San Carlo(IT)
- Università Campus Bio-Medico(IT)
- Azienda Socio Sanitaria Territoriale Lariana(IT)
- Ospedale Sant'Anna(IT)
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo(IT)